TY  - JOUR
AU  - Boni, V
AU  - Pistilli, B
AU  - Braña, I
AU  - Shapiro, G I
AU  - Trigo, J
AU  - Moreno, V
AU  - Castellano, D
AU  - Fernández, C
AU  - Kahatt, C
AU  - Alfaro, V
AU  - Siguero, M
AU  - Zeaiter, A
AU  - Longo, F
AU  - Zaman, K
AU  - Antón, A
AU  - Paredes, A
AU  - Huidobro, G
AU  - Subbiah, V
PY  - 2022
DO  - 10.1016/j.esmoop.2022.100571
UR  - http://hdl.handle.net/10668/22220
T2  - ESMO open
AB  - Lurbinectedin, a selective inhibitor of oncogenic transcription, has shown preclinical antitumor activity against homologous recombination repair-deficient models and preliminary clinical activity in BRCA1/2 breast cancer. This phase II basket...
LA  - en
KW  - BRCA1
KW  - BRCA2
KW  - breast cancer
KW  - lurbinectedin
KW  - phase II
KW  - response rate
KW  - Humans
KW  - Female
KW  - Breast Neoplasms
KW  - Genes, BRCA2
KW  - Genes, BRCA1
KW  - Ribose
KW  - Germ-Line Mutation
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Germ Cells
KW  - Neutropenia
KW  - Hormones
KW  - Adenosine Diphosphate
KW  - BRCA1 Protein
TI  - Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
TY  - research article
VL  - 7
ER  -